CLVSのニュース
Nasdaq delists securities of Tuscan Holdings, Clovis Oncology, Zyversa Therapeutics 2022/12/28 22:09:37 Seeking Alpha
The Nasdaq stock announced on Wednesday delisting of securities of Tuscan Holdings Corp
Why Vallon Pharmaceuticals Shares Are Trading Higher By Over 150%; Here Are 29 Stocks Moving Premarket 2022/12/14 11:30:12 Benzinga
Gainers Vallon Pharmaceuticals, Inc. (NASDAQ: VLON ) shares rose 150.9% to $0.6313 in pre-market trading after the company entered into a definitive merger agreement with GRI Bio. Crown ElectroKinetics Corp. (NASDAQ: CRKN ) shares rose 71.2% to $0.2243 in pre-market trading after gaining 14% on Tuesday. Crown ElectroKinetics, last month, posted a Q3 loss of $0.18 per share. Versus Systems Inc. (NASDAQ: VS ) rose 28% to $1.00 in pre-market trading after gaining around 7% on Tuesday. Versus Systems recently announced pricing of a $2.1 million public offering. Senti Biosciences, Inc. (NASDAQ: SNTI ) rose 17.4% to $1.69 in pre-market trading after dipping more than 21% on Tuesday. Scopus BioPharma Inc. (NASDAQ: SCPS ) shares rose 15.8% to $0.2839 in pre-market trading. Clovis Oncology, Inc. (NASDAQ: CLVS ) rose 12.8% to $0.1503 in pre-market trading after dropping 34% on Tuesday. Clovis Oncology voluntarily initiated a Chapter 11 proceeding in the U.S. Bankruptcy Court and will seek to sell its assets through a court-supervised sales process.
Wall Street’s Take On Clovis Oncology Inc. (NASDAQ: CLVS) Stock. 2022/12/13 13:00:00 Stocks Register
Clovis Oncology Inc. (NASDAQ:CLVS) traded at $0.20 at close of the session on Monday, 12/12/22, made an upward move of 0.65% on its previous day’s price. Looking at the stock we see that its previous close was $0.20 and the beta (5Y monthly) reads 0.47 with the day’s price range being $0.172 – $0.275. In … Wall Street’s Take On Clovis Oncology Inc. (NASDAQ: CLVS) Stock. Read More »
Clovis Oncology files Chapter 11, agrees to sell a drug asset 2022/12/12 22:56:23 Daily Camera
Boulder-based Clovis Oncology Inc. (Nasdaq: CLVS) filed for Chapter 11 bankruptcy protection Sunday. Its filing claims liabilities far exceeding assets.
Clovis Enters Bankruptcy With Deal to Sell Cancer-Drug Candidate to Novartis 2022/12/12 19:05:00 The Wall Street Journal
Clovis Oncology, maker of ovarian cancer drug Rubraca, has filed for chapter 11 and proposed selling a separate therapy to a Novartis affiliate.
Nasdaq delists securities of Tuscan Holdings, Clovis Oncology, Zyversa Therapeutics 2022/12/28 22:09:37 Seeking Alpha
The Nasdaq stock announced on Wednesday delisting of securities of Tuscan Holdings Corp
Why Vallon Pharmaceuticals Shares Are Trading Higher By Over 150%; Here Are 29 Stocks Moving Premarket 2022/12/14 11:30:12 Benzinga
Gainers Vallon Pharmaceuticals, Inc. (NASDAQ: VLON ) shares rose 150.9% to $0.6313 in pre-market trading after the company entered into a definitive merger agreement with GRI Bio. Crown ElectroKinetics Corp. (NASDAQ: CRKN ) shares rose 71.2% to $0.2243 in pre-market trading after gaining 14% on Tuesday. Crown ElectroKinetics, last month, posted a Q3 loss of $0.18 per share. Versus Systems Inc. (NASDAQ: VS ) rose 28% to $1.00 in pre-market trading after gaining around 7% on Tuesday. Versus Systems recently announced pricing of a $2.1 million public offering. Senti Biosciences, Inc. (NASDAQ: SNTI ) rose 17.4% to $1.69 in pre-market trading after dipping more than 21% on Tuesday. Scopus BioPharma Inc. (NASDAQ: SCPS ) shares rose 15.8% to $0.2839 in pre-market trading. Clovis Oncology, Inc. (NASDAQ: CLVS ) rose 12.8% to $0.1503 in pre-market trading after dropping 34% on Tuesday. Clovis Oncology voluntarily initiated a Chapter 11 proceeding in the U.S. Bankruptcy Court and will seek to sell its assets through a court-supervised sales process.
Wall Street’s Take On Clovis Oncology Inc. (NASDAQ: CLVS) Stock. 2022/12/13 13:00:00 Stocks Register
Clovis Oncology Inc. (NASDAQ:CLVS) traded at $0.20 at close of the session on Monday, 12/12/22, made an upward move of 0.65% on its previous day’s price. Looking at the stock we see that its previous close was $0.20 and the beta (5Y monthly) reads 0.47 with the day’s price range being $0.172 – $0.275. In … Wall Street’s Take On Clovis Oncology Inc. (NASDAQ: CLVS) Stock. Read More »
Clovis Oncology files Chapter 11, agrees to sell a drug asset 2022/12/12 22:56:23 Daily Camera
Boulder-based Clovis Oncology Inc. (Nasdaq: CLVS) filed for Chapter 11 bankruptcy protection Sunday. Its filing claims liabilities far exceeding assets.
Clovis Enters Bankruptcy With Deal to Sell Cancer-Drug Candidate to Novartis 2022/12/12 19:05:00 The Wall Street Journal
Clovis Oncology, maker of ovarian cancer drug Rubraca, has filed for chapter 11 and proposed selling a separate therapy to a Novartis affiliate.
Nasdaq delists securities of Tuscan Holdings, Clovis Oncology, Zyversa Therapeutics 2022/12/28 22:09:37 Seeking Alpha
The Nasdaq stock announced on Wednesday delisting of securities of Tuscan Holdings Corp
Why Vallon Pharmaceuticals Shares Are Trading Higher By Over 150%; Here Are 29 Stocks Moving Premarket 2022/12/14 11:30:12 Benzinga
Gainers Vallon Pharmaceuticals, Inc. (NASDAQ: VLON ) shares rose 150.9% to $0.6313 in pre-market trading after the company entered into a definitive merger agreement with GRI Bio. Crown ElectroKinetics Corp. (NASDAQ: CRKN ) shares rose 71.2% to $0.2243 in pre-market trading after gaining 14% on Tuesday. Crown ElectroKinetics, last month, posted a Q3 loss of $0.18 per share. Versus Systems Inc. (NASDAQ: VS ) rose 28% to $1.00 in pre-market trading after gaining around 7% on Tuesday. Versus Systems recently announced pricing of a $2.1 million public offering. Senti Biosciences, Inc. (NASDAQ: SNTI ) rose 17.4% to $1.69 in pre-market trading after dipping more than 21% on Tuesday. Scopus BioPharma Inc. (NASDAQ: SCPS ) shares rose 15.8% to $0.2839 in pre-market trading. Clovis Oncology, Inc. (NASDAQ: CLVS ) rose 12.8% to $0.1503 in pre-market trading after dropping 34% on Tuesday. Clovis Oncology voluntarily initiated a Chapter 11 proceeding in the U.S. Bankruptcy Court and will seek to sell its assets through a court-supervised sales process.
Wall Street’s Take On Clovis Oncology Inc. (NASDAQ: CLVS) Stock. 2022/12/13 13:00:00 Stocks Register
Clovis Oncology Inc. (NASDAQ:CLVS) traded at $0.20 at close of the session on Monday, 12/12/22, made an upward move of 0.65% on its previous day’s price. Looking at the stock we see that its previous close was $0.20 and the beta (5Y monthly) reads 0.47 with the day’s price range being $0.172 – $0.275. In … Wall Street’s Take On Clovis Oncology Inc. (NASDAQ: CLVS) Stock. Read More »